

# Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA

Julie Lucifora,<sup>1,2\*</sup> Yuchen Xia,<sup>1\*</sup> Florian Reisinger,<sup>1</sup> Ke Zhang,<sup>1</sup> Daniela Stadler,<sup>1</sup> Xiaoming Cheng,<sup>1</sup> Martin F. Sprinzl,<sup>1,3</sup> Herwig Koppensteiner,<sup>1</sup> Zuzanna Makowska,<sup>4</sup> Tassilo Volz,<sup>5</sup> Caroline Remouchamps,<sup>6</sup> Wen-Min Chou,<sup>1</sup> Wolfgang E. Thasler,<sup>7</sup> Norbert Hüser,<sup>8</sup> David Durantel,<sup>9</sup> T. Jake Liang,<sup>10</sup> Carsten Münk,<sup>11</sup> Markus H. Heim,<sup>4</sup> Jeffrey L. Browning,<sup>12</sup> Emmanuel Dejardin,<sup>6</sup> Maura Dandri,<sup>2,5</sup> Michael Schindler,<sup>1</sup> Mathias Heikenwalder,<sup>1</sup> †† Ulrike Protzer<sup>1,2††</sup>

<sup>1</sup>Institute of Virology, Technische Universität München–Helmholtz Zentrum München, 81675 Munich, Germany. <sup>2</sup>German Center for Infection Research (DZIF), Munich and Hamburg sites, Germany. <sup>3</sup>1st Medical Department, University Hospital Mainz, 55131 Mainz, Germany. <sup>4</sup>Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland. <sup>5</sup>Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. <sup>6</sup>GIGA-Research Laboratory of Molecular Immunology and Signal Transduction, University of Liège, 4000 Liège, Belgium. <sup>7</sup>Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Grosshadern Hospital, Ludwig Maximilians University, 81377 Munich, Germany. <sup>8</sup>Department of Surgery, University Hospital Rechts der Isar, Technische Universität München, 85748 Munich, Germany. <sup>9</sup>INSERM U1052, CNRS UMR 5286, Cancer Research Center of Lyon, University of Lyon, LabEx DEVweCAN, 69007 Lyon, France. <sup>10</sup>Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA. <sup>11</sup>Clinic for Gastroenterology, Hepatology and Infectiology, Medical Faculty, Heinrich-Heine University, 40225 Düsseldorf, Germany. <sup>12</sup>Department of Immunobiology, Biogen Idec, Cambridge, MA 02142, USA.

\*These authors contributed equally to this work.

†Corresponding author. E-mail: protzer@tum.de (U.P.); heikenwalder@helmholtz-muenchen.de (M.H.)

††These authors contributed equally to this work.

**Current antivirals can control but not eliminate hepatitis-B-virus (HBV), because HBV establishes a stable nuclear cccDNA. Interferon- $\alpha$  treatment can clear HBV but is limited by systemic side effects. Here we describe how interferon- $\alpha$  can induce specific degradation of the nuclear viral DNA without hepatotoxicity and propose lymphotoxin- $\beta$ -receptor activation as a therapeutic alternative. Interferon- $\alpha$  and lymphotoxin- $\beta$ -receptor activation up-regulated APOBEC3A and 3B cytidine-deaminases, respectively, in HBV-infected cells, primary hepatocytes and human liver-needle biopsies. HBV-core protein mediated the interaction with nuclear cccDNA resulting in cytidine-deamination,apurinic/apurimidinic site formation and finally cccDNA degradation that prevented HBV-reactivation. Genomic DNA was not affected. Thus, inducing nuclear deaminases - e.g., by lymphotoxin- $\beta$ -receptor activation - allows development of new therapeutics that combined with existing antivirals may cure hepatitis B.**

Hepatitis B virus (HBV) infection remains a major public health threat with more than 350 million humans chronically infected worldwide at risk of developing end-stage liver disease and hepatocellular carcinoma. Each year, more than 600,000 humans die from consequences of chronic HBV infection. A prophylactic vaccine has been available for hepatitis B for almost thirty years, but the overall number of chronic infections remains high.

HBV is a small, enveloped DNA virus replicating via an RNA intermediate. The encapsidated viral genome consists of a 3.2 kb partially double-stranded relaxed circular DNA (rcDNA) molecule. The virus has optimized its life-cycle for long-term persistence in the liver (1). Upon translocation to the nucleus, the rcDNA genome is converted into a covalently closed circular DNA (cccDNA), which serves as the template

for viral transcription and secures HBV persistence. Nucleos(t)ide analogs are efficient antivirals but only control and do not cure HBV infection owing to the persistence of HBV cccDNA. Therefore, long-term treatment is required, which is expensive and may lead to concomitant resistance (2). Interferon (IFN)- $\alpha$  is licensed for hepatitis B therapy and treatment with this cytokine can result in virus clearance in a proportion of patients; however, its efficacy is limited and high doses are not tolerated (3). Thus, efficient and non-toxic elimination of cccDNA in hepatocytes is a major goal of HBV research.

Using animal models, it has been shown that HBV replication, and in particular the cccDNA content of the liver, can be affected by noncytotoxic mechanisms involving cytokines such as interferons and tumor necrosis factor (TNF), which influence RNA and capsid stability (4–7). Here, we describe an antiviral mechanism that interferes with cccDNA stability and is distinct from influences of antiviral cytokines on cccDNA activity (8).

## High-Dose IFN- $\alpha$ Leads to cccDNA Degradation in HBV-Infected Hepatocytes

IFN- $\alpha$  is known to exert transcriptional, post-transcriptional and epigenetic antiviral effects on HBV (8–12). To study the effect of IFN- $\alpha$  on HBV cccDNA, we used HBV-infected, differentiated HepaRG (dHepaRG) cells and primary human hepatocytes (PHH). These are human cell types susceptible to HBV infection (13, 14) and responsive to IFN- $\alpha$  treatment in vitro (fig. S1A). IFN- $\alpha$  treatment did not lead to detectable hepatotoxicity, even at very high doses (fig. S1B). Treating dHepaRG cells with 500 or 1000 IU/ml IFN- $\alpha$  controlled HBV-DNA synthesis as efficiently as 0.5  $\mu$ M (5-fold EC50) of the nucleoside analog lamivudine (LAM). IFN- $\alpha$ , however, unlike LAM

also significantly reduced expression of HBV-RNA and hepatitis B surface (HBsAg) and e (HBeAg) antigens (Fig. 1A and fig. S1C).

In patients, interruption of LAM treatment results in a rebound of HBV replication (2). Using IFN- $\alpha$ , we observed only a partial or no rebound in HBV-infected dHepaRG cells after treatment cessation (Fig. 1A). Because dHepaRG don't allow virus spread, reduction of HBeAg and lacking rebound indicated an effect of IFN- $\alpha$  on the established HBV cccDNA transcription template besides the known antiviral effects on viral replication (14). By cccDNA-specific qPCR, we determined an 80% reduction of cccDNA after 10 days of treatment (Fig. 1B). Reduction of cccDNA was confirmed by Southern blot analysis (fig. S1D) and was dose dependent (fig. S1E). cccDNA reduction could be induced at any time point (Fig. 1C) and persisted over time (Fig. 1, A and C). The

effect was corroborated in HBV-infected primary human hepatocytes (PHH) (Fig. 1D). In contrast to IFN- $\alpha$ , LAM and even more potent nucleoside analog entecavir (ETV) at very high doses (0.5  $\mu$ M, 1000-fold IC-50) only inhibited reverse transcription and thus HBV replication, but not viral persistence (Fig. 1E). Pretreatment with ETV did not enhance the effect of IFN- $\alpha$  (Fig. 1F) indicating that IFN- $\alpha$  induces the decay of established HBV cccDNA. Since the doses of IFN- $\alpha$  used to achieve this effect were high, we screened for other cytokines showing similar antiviral effects at moderate doses.

### LT $\beta$ R Activation Controls HBV and Leads to cccDNA Degradation in HBV-Infected Cells

IFN- $\gamma$  and TNF- $\alpha$  are known to control HBV in a noncytopathic fashion (4, 7), but cannot be used as therapeutics because they cause severe side effects. We tested the effect of lymphotoxin (LT)  $\beta$  receptor (LT $\beta$ R) activation as an alternative therapeutic option. TNF superfamily members LT $\alpha$ , LT $\beta$  and CD258 are the physiological ligands for LT $\beta$ R and activate several inflammatory, anti-inflammatory, pro- and anti-survival pathways (15). Like hepatocytes (16), dHepaRG (14) and HepG2-H1.3 cells permit HBV replication (17) and express the LT $\beta$ R (fig. S2, A and B). To activate LT $\beta$ R, we used a super-agonistic tetravalent bispecific antibody (BS1) and a bivalent anti-LT $\beta$ R monoclonal antibody (CBE11) (18, 19). As expected, LT $\beta$ R agonists activated canonical (20) and non-canonical nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B) pathways to trigger p100 cleavage (fig. S2C), RelA phosphorylation (fig. S2D), nuclear RelB and RelA translocation (fig. S2, E and F), and up-regulation of known target genes (fig. S2G) without causing any detectable hepatocytotoxicity (fig. S2H).

To test the effect of LT $\beta$ R-activation on HBV infection, dHepaRG cells were treated with BS1 for 12 days starting 24 hours prior to HBV infection. LT $\beta$ R-activation decreased levels of all HBV-markers, including cccDNA by approximately 90% without toxicity (Fig. 2A). The antiviral effect was highly potent with an EC<sub>50</sub> of approximately 0.01  $\mu$ g/mL (fig. S3A). Inhibition of apoptosis did not alter antiviral activity (fig. S4). Neither IFN- $\beta$  nor classic IFN-stimulated genes were up-regulated upon BS1-treatment (fig. S2G) and antiviral activity was independent of IFN-induction (fig. S5).

In vivo, activation of the murine LT $\beta$ R by systemic application of an agonistic antibody (ACH6) induced RelA and RelB nuclear translocation in hepatocytes of HBV-transgenic mice (fig. S6A), reduced HBV viremia (fig. S6B), HBV RNA (fig. S6C) and HBV core (HBc) protein expression in the liver (fig. S6, D and E). Neither signs of hepatocyte apoptosis (fig. S6F) nor elevation of aminotransferases (ALT) (fig. S6G, right panel) were observed indicating good in vivo tolerability of LT $\beta$ R-activation. Since HBV-transgenic mice do not establish HBV cccDNA, this indicated additional antiviral effects of LT $\beta$ R-activation on HBV RNA transcription or stability. Accordingly, discontinuation of LT $\beta$ R-activation induced an immediate, strong rebound of HBV replication (fig. S6G).

To investigate whether LT $\beta$ R-activation would affect established HBV cccDNA in the context of a persistent infection and prevent HBV reactivation, dHepaRG cells were treated with LT $\beta$ R agonists BS1 or CBE11 when a stable, nuclear cccDNA pool had established. All HBV markers, including HBV cccDNA, were reduced upon LT $\beta$ R-activation in HBV-infected dHepaRG cells (Fig. 2, B and C, and fig. S3) as well as in stably transfected HepG2H1.3 cells containing high levels of cccDNA (Fig. 2C). In HBV-infected primary human hepatocytes (PHH), LT $\beta$ R agonisation reduced HBV cccDNA, HBeAg secretion and even more pronounced HBV-DNA replication (Fig. 2D). cccDNA degradation was more effective (up to 95%) when treatment was prolonged (fig. S3, C and D). Treatment interruption for 10 days was almost as efficient as continuous treatment (fig. S3C) indicating that LT $\beta$ R agonists induce a persistent antiviral effect. In contrast to LAM treatment, no rebound of

HBV-replication was observed when BS1 treatment stopped (Fig. 2E). Hence, LT $\beta$ R activation not only suppressed HBV replication but also caused nuclear cccDNA degradation, needed to achieve virus elimination.

### LT $\beta$ R Activation and IFN- $\alpha$ Treatment Induce Deamination and Apurinic/Apyrimidinic (AP) Site Formation in cccDNA

To investigate if cccDNA degradation upon LT $\beta$ R-activation or IFN- $\alpha$  treatment was a result of DNA damage, we examined cccDNA deamination by differential DNA denaturation PCR (3D-PCR) (21). Low denaturing temperatures were sufficient for cccDNA amplification from HBV-infected dHepaRG cells and for PHH treated with IFN- $\alpha$  or BS1, compared with untreated, LAM- or ETV-treated cells (Fig. 3A and fig. S7, C and D). Using a cocktail of recombinant proteins containing all enzymes necessary for DNA repair (preCR mix), we could reverse the denaturation of cccDNA (Fig. 3A, lower panels). The fact, that denaturation temperatures of mock, LAM and ETV treated cells also shifted, indicated that this modification of HBV cccDNA existed even without exposure to exogenous drugs. Deamination of cccDNA (Fig. 3A, right panel) and a drop in cccDNA levels after treatment with CBE11 (table S1) was confirmed in vivo in human liver chimeric uPA-SCID mice infected with HBV. Sequencing analyses showed G/A transitions occurred under treatment (Fig. 3B and fig. S7, A and B) indicating deamination of cytidines to uridine in the HBV cccDNA minus strand. At lower denaturation temperatures G/A transitions became more obvious (Fig. 3C and fig. S7A). These data showed that both LT $\beta$ R-activation and IFN- $\alpha$  treatment led to cccDNA deamination in vitro and in vivo, and help to explain the G/A hypermutation observed in patient samples (21).

Importantly, neither deamination nor mutations of genomic DNA were observed by 3D-PCR (fig. S8A) or by deep sequencing of selected housekeeping or IFN- and LT $\beta$ R-target genes (fig. S8B). This indicated that DNA modifications were specifically targeted to viral cccDNA.

After cytidine deamination, DNA-glycosylases recognize the damaged DNA and cleave N-glycosidic bonds to release the base and create an accessible AP site that can then be cleaved by endonucleases (22). These AP sites can either be repaired, can lead to mutations upon DNA replication or can induce DNA degradation (23). We quantified AP sites created by LT $\beta$ R-activation or IFN- $\alpha$  treatment. However, no increase of AP sites in total DNA extracts from dHepaRG cells or PHH treated with IFN- $\alpha$  or LT $\beta$ R-agonists (fig. S8C) was found, reassuring that our treatments did not lead to detectable damage in genomic DNA. Because AP sites in the small (3.2 kb) cccDNA are very likely to be missed by this analysis, we digested total DNA extracts with an AP-endonuclease (APE1) and then amplified cccDNA by qPCR. APE digestion further decreased cccDNA extracted from dHepaRG cells and PHH treated with IFN- $\alpha$  or LT $\beta$ R-agonists but not with LAM (Fig. 3D). Taken together, our data indicate that both, LT $\beta$ R-activation or IFN- $\alpha$  treatment induced deamination and AP-site formation in HBV cccDNA leading to its degradation, but did not affect genomic DNA.

### LT $\beta$ R Activation and IFN- $\alpha$ Treatment Up-Regulate Expression of Nuclear APOBEC3 Deaminases

IFN- $\alpha$  is known to induce several cytidine deaminases (23, 24). We performed genome-wide expression profiling of HBV-infected dHepaRG cells after LT $\beta$ R-activation (fig. S9A) and classified regulated genes according to their activity and properties (fig. S9B). Hereby, APOBEC3B (A3B) was identified to be the most up-regulated gene with nucleic acid binding properties (fig. S9C).

Analysis of all APOBEC3 family members showed that LT $\beta$ R-activation leads to strong up-regulation of A3B and to minor extent A3G in HBV-infected dHepaRG and PHH, and after systemic application in human liver chimeric uPA-SCID mice (fig. S10A). A3B expression was

induces by LT $\beta$ R-activation in a dose-dependent manner and expression levels steadily increased during continuous treatment (fig. S11) correlating with a concomitant increase in treatment efficacy over time (fig. S3C). Treatment of PHH isolated from different donors with LT $\beta$ R-agonist BS1 resulted in cccDNA degradation at different levels (Fig. 3E and fig. S10B), which could neither be explained by the level of A3B upregulation (Fig. 3E) nor by detection of a previously described (25) genomic deletion of the A3B allele, which seems to correlate with HBV persistence in infected patients (fig. S10, B and C).

In contrast to LT $\beta$ R-activation, IFN- $\alpha$  treatment induced mainly A3A, but also A3F and A3G expression in HBV-infected dHepaRG cells and PHH (fig. S12A), and A3D expression in isolated PHH. By systemic IFN treatment of chimpanzees (26), A3A was strongly upregulated in liver needle biopsies (fig. S12B). Activation of A3A, A3F and A3G after IFN- $\alpha$  treatment was dose- and time-dependent, and decreased after an initial peak despite continuous treatment indicating that cells become refractory to IFN- $\alpha$  (fig. S13). In patients treated with subcutaneous pegylated IFN- $\alpha$ , needle biopsies obtained at different time points confirmed a rapid, strong upregulation of A3A and to a lower extent of A3G in the liver peaking at 16 hours post treatment (fig. S12C). Expression levels declined after this time point and remained low until day 6 post treatment confirming a fast but only transient induction of A3A by IFN- $\alpha$  treatment. Interestingly, the level of A3B or A3A induction in BS-1 and IFN- $\alpha$  treated PHH, respectively, did not directly correlate with the level of cccDNA degradation (Fig. 3E). The fact that IFN- $\alpha$  only induces a transient A3A induction and cells rapidly become refractory to IFN- $\alpha$  may account for the limited effect of IFN- $\alpha$  treatment in HBV-infected patients (3).

#### **APOBEC3A or APOBEC3B Activity Is Essential to Induce cccDNA Degradation**

Among the APOBEC3 family members up-regulated in our experiments, only A3A and A3B located to the nucleus (fig. S14) where they can gain access to cccDNA. To verify that they are indeed responsible for the induction of cccDNA degradation, we overexpressed the HIV-Vif protein (known to promote the degradation of all APOBEC3 proteins except A3B (27, 28)) in dHepaRG cells in a tetracycline-regulated fashion. Expression of HIV-Vif reduced A3A, A3F and A3G expression (fig. S15A), reverted IFN- $\alpha$ -induced cccDNA deamination and prevented cccDNA degradation induced by IFN- $\alpha$  treatment (Fig. 4A). However, expression of HIV-Vif did not alter A3B levels (fig. S15B) and had no impact on cccDNA degradation by LT $\beta$ R-activation (fig. S15C). To specifically address the role of A3A or A3B in cccDNA degradation we further knocked down A3A and A3B in dHepaRG cells under IFN- $\alpha$  or LT $\beta$ R-agonist treatment, respectively, and observed reduced cccDNA deamination (Fig. 4, B and C, left panels). A3A as well as A3B knock-down completely reverted cccDNA degradation, but could not rescue the additional effect of IFN- $\alpha$  or LT $\beta$ R-activation on HBV replication (Fig. 4, B and C, right panels).

To confirm the impact of A3A and A3B on cccDNA deamination, we overexpressed A3A and A3B, respectively, in HBV-replicating HepG2-H1.3 (Fig. 4, D and E). Cytidine-deamination of nuclear cccDNA by A3A and A3B is in accordance with other studies showing that both localize to the nucleus (29) and may be involved in the elimination of foreign DNA (23).

#### **APOBEC3A Interacts with the HBV Core Protein and Binds to cccDNA**

APOBECs have evolved to restrict retroviral replication (30) as well as DNA transfer into cells. They are able to clear foreign nuclear DNA (23, 31), but it remains unclear how HBV cccDNA DNA was recognized and whether it was specifically targeted in our experiments. To assess specificity, we generated cell lines replicating a mammalian replicon

plasmid pEpi containing a linear HBV 1.3-fold overlength sequence. From the linear HBV-genome, HBV replication was initiated and in addition to the pEpi-H1.3 replicon HBV cccDNA was established in the nucleus. Treatment with either IFN- $\alpha$  or LT $\beta$ R-agonist BS1 inhibited HBV replication and resulted in deamination and degradation of HBV cccDNA, but not of the HBV-sequence containing replicon (fig. S16). This indicated that deamination and subsequent degradation induced by both treatments is HBV cccDNA specific.

HBV core protein associates with A3G (32) and HBV cccDNA (33) and thus was a candidate to mediate the targeting of A3 deaminases to HBV cccDNA. Confocal microscopy indicated a co-localization of A3A and A3B with HBV core in different cell lines and PHH (Fig. 5 and fig. S17). Chromatin immunoprecipitation (ChIP) experiments using stably (fig. S18A) or transiently transfected HepG2H1.3 cells or HBV-infected and IFN- $\alpha$  treated dHepaRG cells, showed that HBV core protein and A3A both bind to the cccDNA minichromosome (Fig. 6A). Supporting the possibility that a guardian protein prevents A3A direct binding to DNA (34), we could not detect A3A binding to genomic DNA (fig. S18B) even in the presence of HBV core, which has been reported to also bind to cellular DNA (35).

HBV core protein co-immunoprecipitated A3A in HepG2H1.3 cells and transfected HuH7 cells indicating physical interaction with A3A (fig. S19). Direct interaction of HBV core expressed after HBV infection and A3A induced by IFN- $\alpha$  was confirmed by proximity ligation assay (PLA) (Fig. 6B and fig. S20) and fluorescence resonance energy transfer (FRET) analysis (Fig. 6C). By deletion analysis, we determined that the central region of HBc (aa 77 to 149) is involved in the interaction with A3A (Fig. 6C and fig. S21).

These data suggest that A3A is targeted to cccDNA by interaction with HBV core. No such targeting to genomic DNA has been described so far. Since APOBEC3 deaminases are thought to act on single stranded DNA (36), one possibility is that A3A and A3B act on cccDNA when it is transiently rendered single-stranded by RNA polymerase II before transcription initiation.

We suggest, therefore, the following mechanism of APOBEC-dependent degradation of HBV cccDNA (Fig. 6D). High dose IFN- $\alpha$  treatment or LT $\beta$ R-activation up-regulate the expression of A3A and A3B, respectively, which subsequently co-localize or directly interact with HBV core in infected hepatocytes, translocate to the nucleus, where they are brought into close contact with cccDNA by HBV core. Now, APOBECs can deaminate cccDNA that is transiently rendered single-stranded during transcription. Uracils in HBV cccDNA are recognized and excised by cellular DNA glycosylases leading to formation of AP sites, which are then recognized by cellular AP endonucleases (23) leading to cccDNA digestion. Why cccDNA is degraded instead of being repaired by the cellular DNA repair machinery remains elusive so far. Using a mixture of various enzymes, we were able to repair deaminated cccDNA *in tubo* (Fig. 3A) suggesting induction of an additional factor promoting DNA degradation or an impaired function of the repair machinery rather than a lack of recognition by the repair machinery. Thus, we can only speculate that either the number of AP sites introduced after treatment is too high and exceeds the capacity of the cellular repair machinery or that IFN- $\alpha$  treatment or LT $\beta$ R-activation or even HBV itself (37) modulate the repair machinery. This may shift the equilibrium from cccDNA repair (38) to degradation.

Ideally, a cure for HBV infection needs to eliminate cccDNA. Therefore, cytokines or cytokine-receptor agonists that can trigger HBV cccDNA deamination and its degradation are interesting antiviral candidates. Antivirals that induce A3A/B activity should be combined with nucleos(t)ide analogs to avoid the replenishment of nuclear cccDNA after degradation. LT $\beta$ R-agonists were active at low doses and we did not observe any toxicity *in vitro* or *in vivo* nor did we detect any modification of genomic DNA. Constitutive overexpression of LT $\alpha$ / $\beta$  for more



than one year has been associated with inflammatory liver disease and hepatocellular carcinoma (16). As antivirals, however, LT $\beta$ R-agonists would only be used for a limited period of time minimizing the risk of side effects. Moreover, LT $\beta$ R-activation was already explored as a cancer treatment (18).

A recent study has shown a significantly higher frequency of an A3B deletion allele in persistent HBV carriers and hepatocellular carcinoma patients compared with healthy controls (25). This finding was further supported by the moderate deamination of cccDNA even in absence of treatment, and by the observation that knockdown of A3B in the absence of any treatment increased cccDNA levels. Although deregulated expression of A3A and A3B has been shown to correlate with genomic DNA mutations (39, 40), we did not detect any alterations of genomic DNA using analyses of AP sites, 3D-PCR analysis and deep sequencing of a set of human genes.

Our data indicate that cccDNA degradation is possible and can be induced without side-effects on the infected host cell. An important task will be testing of combinations of nucleos(t)ide analogs with novel antiviral strategies (e.g., LT $\beta$ R agonists or adoptive T-cell therapy (41)) to activate A3A or A3B to cure hepatitis B.

#### References and Notes

1. U. Protzer, M. K. Maini, P. A. Knolle, Living in the liver: hepatic infections. *Nat. Rev. Immunol.* **12**, 201–213 (2012). [doi:10.1038/nri3169](https://doi.org/10.1038/nri3169) [Medline](#)
2. F. Zoulim, Hepatitis B virus resistance to antiviral drugs: where are we going? *Liver Int.* **31**, (Suppl 1), 111–116 (2011). [doi:10.1111/j.1478-3231.2010.02399.x](https://doi.org/10.1111/j.1478-3231.2010.02399.x) [Medline](#)
3. K. Wursthorn, M. Lutgehetmann, M. Dandri, T. Volz, P. Buggisch, B. Zollner, T. Longrich, P. Schirmacher, F. Metzler, M. Zankel, C. Fischer, G. Currie, C. Brosgart, J. Petersen, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBSAg reduction in patients with chronic hepatitis B. *Hepatology* **44**, 675–684 (2006). [doi:10.1002/hep.21282](https://doi.org/10.1002/hep.21282) [Medline](#)
4. L. G. Guidotti, K. Ando, M. V. Hobbs, T. Ishikawa, L. Runkel, R. D. Schreiber, F. V. Chisari, Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. *Proc. Natl. Acad. Sci. U.S.A.* **91**, 3764–3768 (1994). [doi:10.1073/pnas.91.9.3764](https://doi.org/10.1073/pnas.91.9.3764) [Medline](#)
5. L. G. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell, F. V. Chisari, Viral clearance without destruction of infected cells during acute HBV infection. *Science* **284**, 825–829 (1999). [doi:10.1126/science.284.5415.825](https://doi.org/10.1126/science.284.5415.825) [Medline](#)
6. S. F. Wieland, H. C. Spangenberg, R. Thimme, R. H. Purcell, F. V. Chisari, Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 2129–2134 (2004). [doi:10.1073/pnas.0308478100](https://doi.org/10.1073/pnas.0308478100) [Medline](#)
7. H. McClary, R. Koch, F. V. Chisari, L. G. Guidotti, Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. *J. Virol.* **74**, 2255–2264 (2000). [doi:10.1128/JVI.74.5.2255-2264.2000](https://doi.org/10.1128/JVI.74.5.2255-2264.2000) [Medline](#)
8. L. Belloni, L. Allweiss, F. Guerrieri, N. Pediconi, T. Volz, T. Pollicino, J. Petersen, G. Raimondo, M. Dandri, M. Levrero, IFN- $\alpha$  inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. *J. Clin. Invest.* **122**, 529–537 (2012). [doi:10.1172/JCI58847](https://doi.org/10.1172/JCI58847) [Medline](#)
9. A. Rang, S. Günther, H. Will, Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. *J. Hepatol.* **31**, 791–799 (1999). [doi:10.1016/S0168-8278\(99\)80279-7](https://doi.org/10.1016/S0168-8278(99)80279-7) [Medline](#)
10. V. Pasquetto, S. F. Wieland, S. L. Uprichard, M. Tripodi, F. V. Chisari, Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. *J. Virol.* **76**, 5646–5653 (2002). [doi:10.1128/JVI.76.11.5646-5653.2002](https://doi.org/10.1128/JVI.76.11.5646-5653.2002) [Medline](#)
11. S. F. Wieland, L. G. Guidotti, F. V. Chisari, Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. *J. Virol.* **74**, 4165–4173 (2000). [doi:10.1128/JVI.74.9.4165-4173.2000](https://doi.org/10.1128/JVI.74.9.4165-4173.2000) [Medline](#)
12. S. L. Uprichard, S. F. Wieland, A. Althage, F. V. Chisari, Transcriptional and posttranscriptional control of hepatitis B virus gene expression. *Proc. Natl.*

- Acad. Sci. U.S.A.* **100**, 1310–1315 (2003). [doi:10.1073/pnas.252773599](https://doi.org/10.1073/pnas.252773599) [Medline](#)
13. P. Gripon, C. Diot, N. Thézé, I. Fourel, O. Loreal, C. Brechot, C. Guguen-Guillouzo, Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. *J. Virol.* **62**, 4136–4143 (1988). [Medline](#)
14. P. Gripon, S. Rumin, S. Urban, J. Le Seyec, D. Glaise, I. Cannie, C. Guyomard, J. Lucas, C. Trepo, C. Guguen-Guillouzo, Infection of a human hepatoma cell line by hepatitis B virus. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 15655–15660 (2002). [doi:10.1073/pnas.232137699](https://doi.org/10.1073/pnas.232137699) [Medline](#)
15. M. J. Wolf, G. M. Seleznik, N. Zeller, M. Heikenwalder, The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development. *Oncogene* **29**, 5006–5018 (2010). [doi:10.1038/ncr.2010.260](https://doi.org/10.1038/ncr.2010.260) [Medline](#)
16. J. Haybaeck, N. Zeller, M. J. Wolf, A. Weber, U. Wagner, M. O. Kurrer, J. Bremer, G. Iezzi, R. Graf, P. A. Clavien, R. Thimme, H. Blum, S. A. Nedospasov, K. Zatloukal, M. Ramzan, S. Ciesek, T. Pietschmann, P. N. Marche, M. Karin, M. Kopf, J. L. Browning, A. Aguzzi, M. Heikenwalder, A lymphotoxin-driven pathway to hepatocellular carcinoma. *Cancer Cell* **16**, 295–308 (2009). [doi:10.1016/j.ccr.2009.08.021](https://doi.org/10.1016/j.ccr.2009.08.021) [Medline](#)
17. S. Jost, P. Turelli, B. Mangeat, U. Protzer, D. Trono, Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. *J. Virol.* **81**, 10588–10596 (2007). [doi:10.1128/JVI.02489-06](https://doi.org/10.1128/JVI.02489-06) [Medline](#)
18. M. Lukashov, D. LePage, C. Wilson, V. Bailly, E. Garber, A. Lukashin, A. Ngam-ek, W. Zeng, N. Allaire, S. Perrin, X. Xu, K. Szeliga, K. Wortham, R. Kelly, C. Bottiglio, J. Ding, L. Griffith, G. Heaney, E. Silverio, W. Yang, M. Jarpe, S. Fawell, M. Reff, A. Carmillo, K. Miatkowski, J. Amatucci, T. Crowell, H. Prentice, W. Meier, S. M. Violette, F. Mackay, D. Yang, R. Hoffman, J. L. Browning, Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. *Cancer Res.* **66**, 9617–9624 (2006). [doi:10.1158/0008-5472.CAN-06-0217](https://doi.org/10.1158/0008-5472.CAN-06-0217) [Medline](#)
19. X. Hu, M. A. Zimmerman, K. Bardhan, D. Yang, J. L. Waller, G. B. Liles, J. R. Lee, R. Pollock, D. Lev, C. F. Ware, E. Garber, V. Bailly, J. L. Browning, K. Liu, Lymphotoxin  $\beta$  receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of NF- $\kappa$ B activation. *Carcinogenesis* **34**, 1105–1114 (2013). [doi:10.1093/carcin/bgt014](https://doi.org/10.1093/carcin/bgt014) [Medline](#)
20. E. Dejardin, N. M. Droin, M. Delhase, E. Haas, Y. Cao, C. Makris, Z. W. Li, M. Karin, C. F. Ware, D. R. Green, The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. *Immunity* **17**, 525–535 (2002). [doi:10.1016/S1074-7613\(02\)00423-5](https://doi.org/10.1016/S1074-7613(02)00423-5) [Medline](#)
21. R. Suspène, D. Guétard, M. Henry, P. Sommer, S. Wain-Hobson, J. P. Vartanian, Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 8321–8326 (2005). [doi:10.1073/pnas.0408223102](https://doi.org/10.1073/pnas.0408223102) [Medline](#)
22. J. I. Friedman, J. T. Stivers, Detection of damaged DNA bases by DNA glycosylase enzymes. *Biochemistry* **49**, 4957–4967 (2010). [doi:10.1021/bi100593a](https://doi.org/10.1021/bi100593a) [Medline](#)
23. M. D. Stenglein, M. B. Burns, M. Li, J. Lengyel, R. S. Harris, APOBEC3 proteins mediate the clearance of foreign DNA from human cells. *Nat. Struct. Mol. Biol.* **17**, 222–229 (2010). [doi:10.1038/nsmb.1744](https://doi.org/10.1038/nsmb.1744) [Medline](#)
24. M. Bonvin, F. Achermann, I. Greeve, D. Stroka, A. Keogh, D. Inderbitzin, D. Candinas, P. Sommer, S. Wain-Hobson, J. P. Vartanian, J. Greeve, Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. *Hepatology* **43**, 1364–1374 (2006). [doi:10.1002/hep.21187](https://doi.org/10.1002/hep.21187) [Medline](#)
25. T. Zhang, J. Cai, J. Chang, D. Yu, C. Wu, T. Yan, K. Zhai, X. Bi, H. Zhao, J. Xu, W. Tan, C. Qu, D. Lin, Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. *Hum. Mol. Genet.* **22**, 1262–1269 (2013). [doi:10.1093/hmg/dd513](https://doi.org/10.1093/hmg/dd513) [Medline](#)
26. Y. Huang, J. J. Feld, R. K. Sapp, S. Nanda, J. H. Lin, L. M. Blatt, M. W. Fried, K. Murthy, T. J. Liang, Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. *Gastroenterology* **132**, 733–744 (2007). [doi:10.1053/j.gastro.2006.11.045](https://doi.org/10.1053/j.gastro.2006.11.045) [Medline](#)
27. B. P. Doehle, A. Schäfer, B. R. Cullen, Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. *Virology* **339**, 281–288 (2005). [doi:10.1016/j.virol.2005.06.005](https://doi.org/10.1016/j.virol.2005.06.005) [Medline](#)

28. G. Berger, J. Turpin, S. Cordeil, K. Tartour, X. N. Nguyen, R. Mahieux, A. Cimarelli, Functional analysis of the relationship between Vpx and the restriction factor SAMHD1. *J. Biol. Chem.* **287**, 41210–41217 (2012). doi:10.1074/jbc.M112.403816 Medline
29. H. Muckenfuss, M. Hamdorf, U. Held, M. Perkovic, J. Löwer, K. Cichutek, E. Flory, G. G. Schumann, C. Münk, APOBEC3 proteins inhibit human LINE-1 retrotransposition. *J. Biol. Chem.* **281**, 22161–22172 (2006). doi:10.1074/jbc.M601716200 Medline
30. C. Münk, A. Willemsen, I. G. Bravo, An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. *BMC Evol. Biol.* **12**, 71 (2012). doi:10.1186/1471-2148-12-71 Medline
31. M. A. Carpenter, M. Li, A. Rathore, L. Lackey, E. K. Law, A. M. Land, B. Leonard, S. M. Shandilya, M. F. Bohn, C. A. Schiffer, W. L. Brown, R. S. Harris, Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. *J. Biol. Chem.* **287**, 34801–34808 (2012). doi:10.1074/jbc.M112.385161 Medline
32. P. Turelli, B. Mangeat, S. Jost, S. Vianin, D. Trono, Inhibition of hepatitis B virus replication by APOBEC3G. *Science* **303**, 1829 (2004). doi:10.1126/science.1092066 Medline
33. C. T. Bock, S. Schwinn, S. Locarnini, J. Fyfe, M. P. Manns, C. Trautwein, H. Zentgraf, Structural organization of the hepatitis B virus minichromosome. *J. Mol. Biol.* **307**, 183–196 (2001). doi:10.1006/jmbi.2000.4481 Medline
34. M. M. Aynaud, R. Spène, P. O. Vidalain, B. Mussil, D. Guétard, F. Tangy, S. Wain-Hobson, J. P. Vartanian, Human Tribbles 3 protects nuclear DNA from cytidine deamination by APOBEC3A. *J. Biol. Chem.* **287**, 39182–39192 (2012). doi:10.1074/jbc.M112.372722 Medline
35. Y. Guo, W. Kang, X. Lei, Y. Li, A. Xiang, Y. Liu, J. Zhao, J. Zhang, Z. Yan, Hepatitis B viral core protein disrupts human host gene expression by binding to promoter regions. *BMC Genomics* **13**, 563 (2012). doi:10.1186/1471-2164-13-563 Medline
36. H. C. Smith, R. P. Bennett, A. Kizilyer, W. M. McDougall, K. M. Prohaska, Functions and regulation of the APOBEC family of proteins. *Semin. Cell Dev. Biol.* **23**, 258–268 (2012). doi:10.1016/j.semcdb.2011.10.004 Medline
37. T. H. Lee, S. J. Elledge, J. S. Butel, Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. *J. Virol.* **69**, 1107–1114 (1995). Medline
38. K. Kitamura, Z. Wang, S. Chowdhury, M. Simadu, M. Koura, M. Muramatsu, Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA. *PLoS Pathog.* **9**, e1003361 (2013). doi:10.1371/journal.ppat.1003361 Medline
39. S. Landry, I. Narvaiza, D. C. Linfesty, M. D. Weitzman, APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. *EMBO Rep.* **12**, 444–450 (2011). doi:10.1038/embor.2011.46 Medline
40. M. B. Burns, L. Lackey, M. A. Carpenter, A. Rathore, A. M. Land, B. Leonard, E. W. Refsland, D. Kotandeniya, N. Tretyakova, J. B. Nikas, D. Yee, N. A. Temiz, D. E. Donohue, R. M. McDougale, W. L. Brown, E. K. Law, R. S. Harris, APOBEC3B is an enzymatic source of mutation in breast cancer. *Nature* **494**, 366–370 (2013). doi:10.1038/nature11881 Medline
41. K. Krebs, N. Böttinger, L. R. Huang, M. Chmielewski, S. Arzberger, G. Gasteiger, C. Jäger, E. Schmitt, F. Bohne, M. Aichler, W. Uckert, H. Abken, M. Heikenwalder, P. Knolle, U. Protzer, T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. *Gastroenterology* **145**, 456–465 (2013). doi:10.1053/j.gastro.2013.04.047 Medline
42. J. Lucifora, S. Arzberger, D. Durantel, L. Belloni, M. Strubin, M. Levrero, F. Zoulim, O. Hantz, U. Protzer, Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. *J. Hepatol.* **55**, 996–1003 (2011). doi:10.1016/j.jhep.2011.02.015 Medline
43. H. Schulze-Bergkamen, A. Untergasser, A. Dax, H. Vogel, P. Büchler, E. Klar, T. Lehnert, H. Friess, M. W. Büchler, M. Kirschfink, W. Stremmel, P. H. Kramer, M. Müller, U. Protzer, Primary human hepatocytes—a valuable tool for investigation of apoptosis and hepatitis B virus infection. *J. Hepatol.* **38**, 736–744 (2003). doi:10.1016/S0168-8278(03)00120-X Medline
44. S. M. Lee, C. Schelcher, M. Demmel, M. Hauner, W. E. Thasler, Isolation of human hepatocytes by a two-step collagenase perfusion procedure. *J. Vis. Exp.* (79): (2013). Medline
45. W. E. Thasler, T. S. Weiss, K. Schillhorn, P. T. Stoll, B. Irrgang, K. W. Jauch, Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. *Cell Tissue Bank.* **4**, 49–56 (2003). doi:10.1023/A:1026392429112 Medline
46. O. Hantz, R. Parent, D. Durantel, P. Gripon, C. Guguen-Guillouzo, F. Zoulim, Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. *J. Gen. Virol.* **90**, 127–135 (2009). doi:10.1099/vir.0.004861-0 Medline
47. M. Quasdorff, M. Hösel, M. Odenthal, U. Zedler, F. Bohne, P. Gripon, H. P. Dienes, U. Drebbler, D. Stippel, T. Goeser, U. Protzer, A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation. *Cell. Microbiol.* **10**, 1478–1490 (2008). doi:10.1111/j.1462-5822.2008.01141.x Medline
48. U. Protzer, S. Seyfried, M. Quasdorff, G. Sass, M. Svorcova, D. Webb, F. Bohne, M. Hösel, P. Schirmacher, G. Tiegs, Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. *Gastroenterology* **133**, 1156–1165 (2007). doi:10.1053/j.gastro.2007.07.021 Medline
49. A. Untergasser, U. Zedler, A. Langenkamp, M. Hösel, M. Quasdorff, K. Esser, H. P. Dienes, B. Tappertzhofen, W. Kolanus, U. Protzer, Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. *Hepatology* **43**, 539–547 (2006). doi:10.1002/hep.21048 Medline
50. J. Summers, P. M. Smith, A. L. Horwich, Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. *J. Virol.* **64**, 2819–2824 (1990). Medline
51. W. Gao, J. Hu, Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. *J. Virol.* **81**, 6164–6174 (2007). doi:10.1128/JVI.02721-06 Medline
52. G. K. Smyth, Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat. Appl. Genet. Mol. Biol.* **3**, Article3 (2004).
53. C. Banning, J. Votteler, D. Hoffmann, H. Koppensteiner, M. Warmer, R. Reimer, F. Kirchhoff, U. Schubert, J. Hauber, M. Schindler, A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. *PLoS ONE* **5**, e9344 (2010). doi:10.1371/journal.pone.0009344 Medline
54. K. Arnold, L. Bordoli, J. Kopp, T. Schwede, The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. *Bioinformatics* **22**, 195–201 (2006). doi:10.1093/bioinformatics/bti770 Medline
55. S. A. Wynne, R. A. Crowther, A. G. Leslie, The crystal structure of the human hepatitis B virus capsid. *Mol. Cell* **3**, 771–780 (1999). doi:10.1016/S1097-2765(01)80009-5 Medline
56. I. J. Byeon *et al.*, NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. *Nat. Commun.* **4**, 1890 (2013).
57. A. W. Ghoorah, M. D. Devignes, M. Smaïl-Tabbone, D. W. Ritchie, Protein docking using case-based reasoning. *Proteins* **81**, 2150–2158 (2013). doi:10.1002/prot.24433 Medline
58. R. A. Sayle, E. J. Milner-White, RASMOL: biomolecular graphics for all. *Trends Biochem. Sci.* **20**, 374–376 (1995). doi:10.1016/S0968-0004(00)89080-5 Medline
59. L. G. Guidotti, B. Matzke, H. Schaller, F. V. Chisari, High-level hepatitis B virus replication in transgenic mice. *J. Virol.* **69**, 6158–6169 (1995). Medline
60. M. Dandri, M. R. Burda, E. Török, J. M. Pollok, A. Iwanska, G. Sommer, X. Rogiers, C. E. Rogler, S. Gupta, H. Will, H. Greten, J. Petersen, Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. *Hepatology* **33**, 981–988 (2001). doi:10.1053/jhep.2001.23314 Medline
61. M. Lütgehetmann, T. Bornscheuer, T. Volz, L. Allweiss, J. H. Bockmann, J. M. Pollok, A. W. Lohse, J. Petersen, M. Dandri, Hepatitis B virus limits response of human hepatocytes to interferon- $\alpha$  in chimeric mice. *Gastroenterology* **140**, 2074–2083, e1–e2 (2011). doi:10.1053/j.gastro.2011.02.057 Medline
62. M. Sarasin-Filipowicz, E. J. Oakeley, F. H. Duong, V. Christen, L. Terracciano, W. Filipowicz, M. H. Heim, Interferon signaling and treatment outcome in chronic hepatitis C. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 7034–7039 (2008). doi:10.1073/pnas.0707882105 Medline

**Acknowledgments:** We would like to thank Romina Bester, Theresa Asen, Kerstin Ackermann, Kathrin Kappes, Martin Feuerherd, Robert Baier, Ruth Hillermann, Ute Finkel, Aikatherini Krikoni and Fang Zhang for their

technical support, Prof. Luigi Terracciano for analysis of acute hepatitis patients, Prof. Frank Chisari for providing HBV transgenic mice (HBV 1.3.32), Prof. Thorsten Buch and Olivia Prazeres da Costa for help with array analysis and data discussions, Lena Allweiss and Anne Groth for help by generating and treating humanized uPA/SCID mice, as well as Siemens Healthcare Diagnostics for providing reagents. The study was supported by grants from FCC (Fédération belge Contre le Cancer) to ED, an ERC Starting grant (LiverCancerMechanism) to MH, the German Research Foundation (SFB 841 to MD, SFB TR 36 to MH, SFB TR 22), the Peter-Hans Hofschneider foundation and the Helmholtz Alliances HAIT (to UP) and PCCC (to MH). We acknowledge the support of the nonprofit foundation HPCR, which holds human tissue on trust, making it broadly available for research on an ethical and legal basis. Patent application EP12006XXX filed at the European patent office: 'Lymphotoxin signaling activation and its downstream mediators eliminate HBV ccc DNA'. Microarray data have been submitted to the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>) and have the accession number GSE46667. Human liver-chimeric UPA/SCID mice were handled in accordance with protocols approved by the Ethical Committee of the city and state of Hamburg (permission number G12/015). Experiments with HBV-transgenic mice were performed in accordance to the German legislation governing animal studies and the Principles of Laboratory Animal Care guidelines, NIH (55.1-1-54-2531.3-27-08). The study protocol for the experiment with Chimpanzee was approved at the Southwest Foundation for Biomedical Research, San Antonio, TX (IACUC 869 PT, approved in 2004).

#### **Supplementary Materials**

[www.sciencemag.org/cgi/content/full/science.1243462/DC1](http://www.sciencemag.org/cgi/content/full/science.1243462/DC1)

Materials and Methods

Figs. S1 to S21


Table S1

References (42–62)


18 July 2013; accepted 5 February 2014

Published online 20 February 2014

10.1126/science.1243462




**Fig. 1. Degradation of cccDNA in IFN-α treated HepaRG cells and primary human hepatocytes.** (A, B, C, E, and F) HBV-infected dHepaRG were treated with IFN-α at day 10 post-infection (dpi). Different regimens of treatment were applied as indicated. (D) HBV-infected primary human hepatocyte (PHH) were treated with IFN-α at dpi 3 for 13 days. Levels of HBeAg, total intracellular DNA and cccDNA are given relative to mock treated cells. LAM: lamivudine; ETV: entecavir. Mean values  $\pm$  standard deviation of replicates from independent experiments are given; data were analyzed by *t* test. \*  $p < 0.05$ , \*\*  $p < 0.01$  and \*\*\*  $p < 0.001$ .




**Fig. 2. LT $\beta$ R-activation inhibits HBV infection and leads to cccDNA degradation in HepaRG cells and PHH.** (A and B) HBV-infected dHepaRG were treated with BS1, CBE11, hu-IgG control or lamivudine (LAM). (A) Treatment started 24h before infection for 12 days or (B) at 18 dpi for 10 days. Levels of the indicated HBV markers as well as cell viability are given relative to untreated controls (mock). (C) cccDNA levels were analyzed after 14 days of BS1 treatment by Southern blot in HBV-infected dHepaRG and HBV-replicating HepG2H1.3 cells. Supercoiled cccDNA bands were identified by their expected size and linearization upon *EcoRI* digestion (3,2 kb). (D) PHH were infected with HBV and treated with BS1 at 7 dpi for 10 days. Levels of the indicated HBV markers were compared to untreated PHH of the same donor (donor 3) (mock). (E) HBV-infected dHepaRG were treated with BS1, hu-IgG control or LAM. Intracellular HBV-DNA was analyzed 8 and 14 days after treatment cessation. Mean values  $\pm$  standard deviation of replicates from independent experiments are given; data were analyzed by *t* test. \*  $p < 0.05$ , \*\*\*  $p < 0.001$ .







**Fig. 3. Deamination and AP-site formation in cccDNA upon IFN- $\alpha$  treatment and LT $\beta$ R-activation.** (A) dHepaRG (left) and PHH (middle panel) were infected with HBV and treated with IFN- $\alpha$ , BS1 or LAM. Human chimeric uPA/SCID mice were treated with CBE11 or hu-IgG control (right panel). 3D-PCR analyses were performed on cccDNA left either untreated (upper panels) or treated with a PreCR mix (lower panels). (B and C) 3D-PCR products from HBV-infected dHepaRG cells treated as indicated (IFN- $\alpha$ , BS1 or mock) were cloned and sequenced and mutations were analyzed. (D) Total DNA extracts from HBV-infected cells treated as indicated were digested with APE1, and cccDNA content was compared to mock-treated cells. In (B), (C), and (D), mean values  $\pm$  standard deviation of biological triplicates from two independent experiments are given; data were analyzed by *t* test. \*  $p < 0.05$ , \*\*  $p < 0.01$ . (E) PHH were infected with HBV and treated with BS1 or IFN- $\alpha$  at 7 dpi for 10 days. Levels of the indicated cccDNA as well as A3A and A3B mRNA expression were compared to untreated PHH (mock) of the same donor.



**Fig. 4. Analysis of cccDNA deamination and degradation.** (A to C) cccDNA denaturation was analyzed by 3D-PCR (left panels); levels of HBeAg, total intracellular DNA and cccDNA are given relative to mock treated cells (right panels). (A) dHepaRG-tA-Vif cells treated with IFN- $\alpha$  for 10 days with and without doxycycline (dox)-induced HIV-Vif expression. HBV-infected dHepaRG cells treated with (B) IFN- $\alpha$  or (C) BS1 transfected with siRNA against A3A or A3B, respectively, or sequence nonspecific siRNA (sicontrol). Mean values  $\pm$  standard deviation of independent replicates and experiments are given; data were analyzed by *t* test. \*  $p < 0.05$ , \*\*  $p < 0.01$  and \*\*\*  $p < 0.001$ . (D) cccDNA denaturation analysis by 3D-PCR in HepG2-H1.3 cells overexpressing A3A or (E) A3B from lentiviral vector plasmid pLenti6.3 or pTR600, respectively, for 5 days.



**Fig. 5. Co-localization of A3A and A3B with HBV core protein (HBc).** (A) HuH7 cells were co-transfected with an HBV1.1-fold genome and A3A-Flag or A3B-Flag expressing plasmids and stained using DAPI, anti-HBc and anti-FLAG antibodies. (B) HBV-infected dHepaRG and PHH were treated with IFN- $\alpha$  at day 7 post infection for 3 days. A3A and HBc were analyzed by immunofluorescence staining. Right panels indicate z stacks taken at the dotted lines.



**Fig. 6. Interaction of A3A, HBV core protein (HBc) and cccDNA.** (A) Chromatin immunoprecipitation (ChIP) was performed using lysates of HepG2H1.3 cells transfected with A3A-expressing plasmid, or HBV-infected dHepaRG cells treated with IFN- $\alpha$  for 3 days. IPs using antibodies against histone H3, A3A, HBc and control rabbit IgG (RlgG) were analyzed by qPCR for cccDNA. (B) Interaction between HBc and A3A was assessed by proximity ligation assay (PLA) in HBV-infected, IFN- $\alpha$  treated dHepaRG. PLA-spots were quantified in single cells by software-based spot-counting. Data were analyzed by one-way ANOVA. \*\*  $p < 0.01$  and \*\*\*  $p < 0.001$ . (C) Serial HBV core-deletion mutants (left panel) were fused to CFP and interaction with A3A-YFP was assessed by FACS-FRET in HuH7.5 hepatoma cells (right panel). Cells cotransfected with CFP and YFP served as controls to exclude false positive FRET and subtract background signals. A CFP-YFP fusion construct was used as positive control. Mean values  $\pm$  standard deviation of FRET-positive cells from 3-4 independent experiments are given. Black boxes indicate shared regions of HBc mutants giving a FRET signal. (D) Model of cccDNA degradation induced by IFN- $\alpha$  treatment or LT $\beta$ R-activation.